Aurobindo Pharma’s US Inhalation Push: Lannett Launches Generic Advair Diskus
Aurobindo Pharma announced on August 31, 2026, that its wholly owned step-down subsidiary, Lannett Company LLC, has launched the generic version of Advair Diskus® in the US market.
The product has been launched in 100/50 mcg and 250/50 mcg strengths and is the generic equivalent of Advair Diskus®, a product of GSK plc.
First US Commercial Launch From Inhalation Pipeline
The launch is significant for Aurobindo Pharma because it marks the first commercialized product from the company’s inhalation pipeline in the US.
Aurobindo said the launch reflects its continued focus on expanding its portfolio of complex and differentiated inhalation products.
The company’s move into the US inhalation market adds another category to its existing global pharmaceutical portfolio and could provide a platform for further commercialization of inhalation products in the future.
Advair Generic Targets Asthma and COPD
The generic product contains fluticasone propionate and salmeterol inhalation powder.
The combination therapy is indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
The launch gives Lannett and the Aurobindo Pharma group an opportunity to participate in the US market for respiratory medicines through a generic equivalent of an established branded product.
Strategic Importance for Aurobindo Pharma
The key development for investors is not just the launch of a single generic product, but the company’s entry into commercialization of its inhalation pipeline in the US.
Complex inhalation products generally require specialized development, manufacturing and regulatory capabilities. Aurobindo’s emphasis on differentiated inhalation products therefore points toward a strategy of expanding beyond conventional generic medicines into more complex pharmaceutical opportunities.
A successful launch and subsequent expansion of the inhalation portfolio could strengthen the company’s presence in the US respiratory medicines market.
Aurobindo Pharma’s Global Pharmaceutical Business
Aurobindo Pharma is an integrated pharmaceutical company headquartered in Hyderabad, India, with operations spanning generic pharmaceuticals, branded specialty products and active pharmaceutical ingredients.
The company has a presence across more than 150 countries and operates 30+ manufacturing and packaging facilities approved by various international regulatory agencies.
Its portfolio covers therapeutic areas including central nervous system treatments, anti-retroviral medicines, cardiovascular products, antibiotics, gastroenterology, anti-diabetic and anti-allergic products.
Investor Takeaway
Aurobindo Pharma’s latest announcement marks an important step in its US inhalation strategy.
The launch of generic Advair Diskus through Lannett provides the company with its first commercial product from the inhalation pipeline in the US, while reinforcing its focus on complex and differentiated pharmaceutical products.
For investors, the key factors to monitor will be the commercial performance of the product, further US inhalation launches and the company’s ability to build a broader respiratory portfolio.
The development therefore adds another potential growth avenue to Aurobindo Pharma’s established US generic pharmaceutical business.
Disclaimer: This article is based on information contained in Aurobindo Pharma Limited’s corporate announcement dated August 31, 2026. The launch does not by itself indicate any specific revenue or profit impact. Investors should independently evaluate the company’s financial performance, regulatory developments and business prospects before making investment decisions.